Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Long-Term Investments (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Long-Term Investments for 6 consecutive years, with $470.5 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 28.39% to $470.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $470.5 million through Dec 2025, down 28.39% year-over-year, with the annual reading at $470.5 million for FY2025, 28.39% down from the prior year.
  • Long-Term Investments for Q4 2025 was $470.5 million at Relay Therapeutics, down from $504.9 million in the prior quarter.
  • The five-year high for Long-Term Investments was $847.1 million in Q4 2022, with the low at $387.9 million in Q3 2021.
  • Average Long-Term Investments over 5 years is $619.7 million, with a median of $636.9 million recorded in 2024.
  • The sharpest move saw Long-Term Investments soared 194.23% in 2021, then decreased 28.42% in 2023.
  • Over 5 years, Long-Term Investments stood at $678.0 million in 2021, then grew by 24.95% to $847.1 million in 2022, then fell by 28.42% to $606.4 million in 2023, then rose by 8.36% to $657.0 million in 2024, then dropped by 28.39% to $470.5 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $470.5 million, $504.9 million, and $542.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.